Let's Talk About Sex

2022]Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin.Simon JA, Clayton AH, Kim NN, Patel S. Sex Med. Review Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. 2015]Review Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.Dhanuka I, Simon JA.

• Flibanserin is classified as a centrally acting serotonergic agent.
• It is not a testosterone-based therapy, unlike some other treatments.
• The FDA approval was based on studies showing increased sexual desire in women.
• The medication can cause sleep disturbances, including somnolence.
• Flibanserin has a potential for drug interactions with CYP3A4 inhibitors.
• It is recommended to start treatment at least 4 weeks before expecting improvement.
• Discontinuation of the drug normally leads to the loss of effects.
• The drug's efficacy is modest compared to some male sexual dysfunction drugs.
• Initiation of therapy involves screening for contraindications.

Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment. 2020]Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.Kingsberg SA, Simon JA. This medication is used to treat women who have not gone through menopause who have low sexual desire and are concerned about it. Flibanserin should not be used to treat low sexual desire caused by: a medical or mental/mood disorder, problems in the relationship, or the effects of other drugs. This medication should not be used by women who have gone through menopause, or by men. Flibanserin is not used to enhance sexual performance. 100 mg Brand(s): Addyi(R), Sprout film-coated Read the Medication Guide provided by your pharmacist before you start taking flibanserin and each time you get a refill.

What special precautions should I follow?

Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder in Premenopausal Women. Flibanserin Efficacy and Safety in Premenopausal Women With Generalized Acquired Hypoactive Sexual Desire Disorder. Flibanserin for Treating Hypoactive Sexual Desire Disorder. Clayton AH, Croft HA, Yuan J, Brown L, Kissling R. Safety of Flibanserin in Women Treated With Antidepressants: A Randomized, Placebo-Controlled Study.

Hazard Classifications

Accidental Flibanserin Ingestion in Children Causing Acute Respiratory and Central Nervous System Depression: What Health Care Professionals Need to Know. Next-day residual effects of flibanserin on simulated driving performance in premenopausal women. 2017 Jul;32(4) [PMC free article: PMC5697607] [PubMed: 28568608] Abstracts from the 2017 American College of Medical Toxicology (ACMT) Annual Scientific Meeting. Disclosure: China Pierrelus declares no relevant financial relationships with ineligible companies. Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies. If you have any questions, ask your doctor or pharmacist. Take this medication by mouth as directed by your doctor, usually once daily at bedtime. Take flibanserin only at bedtime to reduce your risk of low blood pressure, fainting, and drowsiness while you are awake. After taking flibanserin, do not drink any alcohol until the next day.

Avoid eating grapefruit or drinking grapefruit juice while using this medication unless your doctor or pharmacist says you may do so safely. Grapefruit can increase the chance of side effects with this medicine. Ask your doctor or pharmacist for more details. Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day. Tell your doctor if your condition does not get better after 8 weeks of treatment. If you miss a dose, skip the missed dose.

Before Using

Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. National Center for Biotechnology Information (US); Bethesda (MD): Sep 23, 2019. Female Sexual Dysfunction: ACOG Practice Bulletin Summary, NUMBER 213. Treatment of Hypoactive Sexual Desire Disorder Among Women: General Considerations and Pharmacological Options. Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women.

Who should not use Addyi?

Roles of 5-HT receptors in the release and action of secretin on pancreatic secretion in rats. [The pharmacological basis of the serotonin system: Application to antidepressant response]. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R. Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

What should I tell my healthcare provider before using Addyi?

National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 26, 2018. Female sexual dysfunction: a focus on flibanserin. Gelman F, Atrio J. Flibanserin for hypoactive sexual desire disorder: place in therapy. Holt H, Tingen J. Take your next dose at bedtime the next day. Do not double the dose to catch up. Warning: Breastfeeding is not recommended while using this drug. Alcohol and marijuana may intensify this effect. Use care when operating a vehicle, vessel (e.g., boat), or machinery. If you drink alcohol, discuss the safe use of alcohol while using this medication with your healthcare professional. Do not eat grapefruit or drink grapefruit juice at any time while taking this medication. See also Warning and How to Use sections. Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist.

Pharmacist tips for Addyi (flibanserin)

Flibanserin is a novel pharmacological agent for treating acquired, generalized HSDD in premenopausal women. The flibanserin medication guide provides specific instructions to educate patients on safe alcohol consumption while taking flibanserin, aiming to mitigate the risk of hypotension and syncope. Similar to other CNS depressant medications, patients should receive counseling about the increased risk of CNS depression when coadministered with flibanserin. Moreover, patients should receive guidance on potential adverse events associated with the medication, as discussed in the previous section. In addition, healthcare team members should conduct a comprehensive medication review to identify any drugs mentioned earlier that may interact with flibanserin.

InChI key

Patient education should also emphasize the significance of bedtime dosing to prevent hypotension and syncope. Flibanserin has been available in the United States for over 8 years, and continuous postmarketing safety monitoring has not revealed any new safety signals. Furthermore, a 52-week open-label extension study involving 1723 premenopausal women with acquired, generalized HSDD who had previously completed a flibanserin trial demonstrated that the medication was well-tolerated. The study also found that sexual function improved in women who were not FSFI remitters at baseline, and this improvement was sustained in those who were remitters at baseline. Interprofessional healthcare team members must be aware of the obstacles preventing them from prescribing flibanserin to patients.

Drug Interactions Table

This will help patients receive the most effective and personalized treatment for HSDD. Some of these barriers include the high treatment cost, potential drug interactions, and individual-specific adverse effects. The availability of flibanserin, along with non-pharmacological therapies, will enhance the treatment options for premenopausal women affected by HSDD. Effective communication and coordination among clinicians (MD, DO, NP, and PA), pharmacists, specialists, and nurses are pivotal in optimizing patient outcomes related to flibanserin pharmacotherapy and reducing the likelihood of potential adverse drug reactions. Female hypoactive sexual desire disorder: epidemiology, diagnosis and treatment. Do not start, stop, or change the dosage of any medicines without your doctor's approval. Other medications can affect the removal of flibanserin from your body, which may affect how flibanserin works. Examples include azole antifungals (such as fluconazole, ketoconazole), certain calcium channel blockers (such as diltiazem, verapamil), macrolide antibiotics (such as clarithromycin, erythromycin), nefazodone, rifamycins (such as rifabutin, rifampin), ritonavir, St.

What does it ‘treat’?

Disclosure: Karen Carlson declares no relevant financial relationships with ineligible companies. Review New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin. 2017]Review New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin.Jayne CJ, Heard MJ, Zubair S, Johnson DL. 2020]Review Evaluation of safety for flibanserin.Clayton AH, Brown L, Kim NN. Clinically Meaningful Benefit in Women with Hypoactive creams for erectile dysfunction Sexual Desire Disorder Treated with Flibanserin. John's wort, drugs used to treat seizures (such as carbamazepine, phenytoin), among others.

• Direct comparison trials between flibanserin and bremelanotide are lacking.
• Choice of treatment depends on patient preference, risk profile, and cost.
• Psychological and interpersonal factors are important contributors to HSDD.
• Combining medication with sex therapy or counseling may improve outcomes.
• Flibanserin does not increase libido in individuals without HSDD.
• It is not approved or intended for use as a recreational or enhancement drug.
• Off-label use, such as in postmenopausal women or men, is not supported by evidence.
• Healthcare providers must complete an online knowledge assessment for REMS certification.
• Certification must be renewed periodically according to the REMS program.

Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or antihistamines (such as cetirizine, diphenhydramine). Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely. Store at room temperature away from light and moisture. Keep all medications away from children and pets. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company. Ask a clinical question and tap into Healio AI's knowledge base.

Healio's exclusive daily news coverage of clinical data Selected from data included with permission and copyrighted by FDB, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution in professional health care settings.

• Flibanserin was one of the first drugs approved specifically for female hypoactive sexual desire.
• The drug's mechanism is different from that of PDE5 inhibitors used in men.
• It can induce side effects like low blood pressure and syncope, requiring caution.
• Patients should be monitored regularly for adverse effects during therapy.
• Flibanserin's approval marked significant progress in women's sexual health.
• It should be used with caution in women on other serotonergic medications.
• The medication's safety profile is still under ongoing research.
• It is not indicated for women with a history of alcohol abuse.
• The benefits of flibanserin are generally seen as modest but meaningful for some women.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of your healthcare professional.

• Flibanserin, a serotonin receptor modulator, was initially investigated for depression.
• Its approval marked a historic moment in treating female sexual dysfunction.
• The medication's side effects necessitate careful patient education.
• Efficacy is often supported by patient-reported improvements in desire.
• It does not function as an aphrodisiac but affects brain chemistry.
• Flibanserin therapy requires adherence to dosing instructions.
• Women with low libido due to other health issues may not benefit from it.
• Its role is to complement behavioral or psychological therapy if needed.
• Research continues into better options for treating female hypoactive sexual desire.

The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you.